argenx is a clinical-stage biotechnology company developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Co.'s SIMPLE Antibody Platform, based on the llama immune system, allows Co. to exploit complex targets, and its three antibody Fc engineering technologies are designed to enable Co. to expand the therapeutic index of its product candidates. Co. has two therapeutic candidates discovered via its Innovative Access Program: ARGX-117, which targets the complement compound C2 with potential in severe autoimmune indications; and ARGX-118, which addresses Galectin-10 and targets airway inflammation. The ARGX stock yearly return is shown above.
The yearly return on the ARGX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ARGX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|